Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.5% - What's Next?
Ocular Therapeutix (NASDAQ:OCUL) shares increased by 9.5% on Friday, despite trading on significantly low volume. The company has a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $23.78, indicating substantial upside. However, the company reported weak Q4 fundamentals, including an earnings beat but a 22.4% year-over-year revenue decline, and has negative profitability metrics and recent insider share sales.
Ocular Therapeutix Sees Mixed Results with Wet AMD Trial Boost and Stocks Dive
Ocular Therapeutix (OCUL) is experiencing mixed results, with stock prices fluctuating due to promising Phase 3 trial data for its wet AMD treatment, Axpaxli, and simultaneous underperformance in revenue targets. Despite a recent stock selloff, analysts maintain a bullish outlook, foreseeing FDA approval for Axpaxli. The company is actively pursuing strategic growth, including the appointment of a new Global Chief Commercial Officer, amidst financial challenges and market volatility.
Ocular Therapeutix’s Axpaxli Hits Key Milestone in Eye Treatment
Ocular Therapeutix's stock saw a 12.94% increase following positive FDA designations and clinical trial results for its eye treatment, Axpaxli, despite mixed Q4 earnings where EPS beat expectations but revenue fell short. The company faces competitive pressures and negative profitability but maintains strong liquidity and a heavy investment in research and innovation. Investors remain speculative, awaiting further clarity on Axpaxli's regulatory approvals and market debut.
Needham cuts Ocular Therapeutix stock price target on trial results
Needham has reduced its price target for Ocular Therapeutix (NASDAQ:OCUL) to $18 from $20, while maintaining a Buy rating, following the company's SOL-1 trial data release. Despite meeting key endpoints, the trial showed a narrower-than-expected efficacy gap due to Eylea's outperformance, leading to adjusted peak sales projections for Axpaxli. However, the firm believes the results should still support FDA approval, and analysts maintain a "Strong Buy" consensus with significant upside potential, viewing the recent stock valuation reset as overdone.
Needham & Company LLC Has Lowered Expectations for Ocular Therapeutix (NASDAQ:OCUL) Stock Price
Needham & Company LLC has reduced its price target for Ocular Therapeutix (NASDAQ:OCUL) from $20 to $18, while maintaining a "buy" rating, indicating a potential 156% upside. This adjustment follows the biopharmaceutical company reporting a quarterly loss of ($0.29) EPS, beating estimates, but revenue of $13.25 million, falling short of expectations and marking a 22.4% year-over-year decline. Despite the lowered target, the consensus among analysts remains a "Moderate Buy" with an average price target of $23.78, even as company insiders have sold shares totaling approximately $1.5 million in recent months.
Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. (OCUL) whose stock declined approximately 27% after the company announced topline results from its SOL-1 Phase 3 trial. The firm is examining whether Ocular complied with federal securities laws following the disclosure that patients maintained vision at varying percentages over 9 and 12 months, and approximately 69% were rescue-free at 52 weeks. Shareholders who suffered losses are encouraged to contact Johnson Fistel for more information about potentially recovering their investment losses.
Is It Time To Reassess Ocular Therapeutix (OCUL) After The Recent Share Price Slump
Ocular Therapeutix (OCUL) has experienced significant share price volatility, with recent declines despite a 21.8% three-year return. A Discounted Cash Flow (DCF) analysis suggests the stock is heavily undervalued at $86.45 per share compared to its current price of $6.99, implying a 91.9% discount. However, a Price-to-Sales (P/S) ratio of 29.29x, compared to an industry average of 4.44x and Simply Wall St's Fair Ratio of 0.24x, suggests the company is overvalued based on sales.
Ocular Therapeutix COO Notman sells $103,471 in stock By Investing.com
Donald Notman, COO of Ocular Therapeutix (NASDAQ: OCUL), sold 11,446 shares of common stock totaling $103,471. This transaction occurred amidst several other significant company announcements, including positive Phase 3 trial results for their investigational treatment AXPAXLI for wet age-related macular degeneration, an "Outperform" rating from RBC Capital, and key appointments to the executive team. The company is advancing its New Drug Application timeline for AXPAXLI and conducting ongoing Phase 3 trials for additional indications.
Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors in Ocular Therapeutix, Inc. (NASDAQ: OCUL) following a significant 27% drop in the company's stock price after the announcement of its SOL-1 Phase 3 trial results. The law firm is examining whether Ocular's executive officers complied with federal securities laws and is encouraging affected shareholders to join their investigation to potentially recover losses.
Ocular Therapeutix reports positive phase 3 SOL-1 superiority data for wet AMD
Ocular Therapeutix announced positive topline results from its SOL-1 phase 3 superiority study for AXPAXLI (OTX-TKI), an investigational treatment for wet age-related macular degeneration (wet AMD). The study demonstrated AXPAXLI's superiority over aflibercept in maintaining visual acuity and central subfield thickness, with a high percentage of patients remaining rescue-free through Week 52. The company plans to submit a New Drug Application (NDA) for AXPAXLI for wet AMD in the coming months, aiming for a superiority label and best-in-disease durability.
Ocular Therapeutix (OCUL) Rating Maintained at Buy by Chardan Ca
Chardan Capital has reaffirmed its "Buy" rating for Ocular Therapeutix (OCUL), keeping its price target at $21.00. This reinforces a consistent positive outlook from several analysts for the biotechnology company, which specializes in eye therapies. While analysts project an average target price of $25.17, GuruFocus estimates a one-year fair value of $3.42, suggesting a potential downside.
Ocular Therapeutix COO Notman sells $103,471 in stock By Investing.com
Donald Notman, Chief Operating Officer of Ocular Therapeutix, INC (NASDAQ:OCUL), sold 11,446 shares for $103,471 on February 12, 2026. This transaction involved shares sold at a weighted average price of $9.04, with prices ranging from $8.9950 to $9.0950. Following the sale, Notman still directly owns 366,356 shares, and the company recently announced positive Phase 3 trial results for its investigational treatment AXPAXLI, along with a reiterated Outperform rating from RBC Capital.
Summer Road LLC Sells 1,307,811 Shares of Ocular Therapeutix, Inc. $OCUL
Summer Road LLC has reduced its stake in Ocular Therapeutix (NASDAQ:OCUL) by selling 1,307,811 shares, now holding 12,579,657 shares, which represents about 7.23% of the company and 98.3% of the firm's portfolio. Despite a recent positive Phase 3 trial result for its eye drug SOL-1 against Regeneron’s Eylea, the stock plummeted over 20% due to investor skepticism regarding the modest benefit and comparator issues. Analysts generally maintain a "Moderate Buy" rating with a consensus price target of $24.00, despite the company's negative EPS, declining revenue, and recent insider selling.
Ocular Therapeutix COO Notman sells $103,471 in stock
Donald Notman, Chief Operating Officer of Ocular Therapeutix (NASDAQ:OCUL), sold 11,446 shares of company stock for a total of $103,471. This transaction follows positive news regarding AXPAXLI, the company's investigational treatment for wet age-related macular degeneration, which met its primary endpoint in a Phase 3 trial. RBC Capital has maintained an Outperform rating on Ocular Therapeutix with a $30.00 price target.
Ocular Therapeutix Shares Jump 28% as SOL-1 Nears Key Data
Ocular Therapeutix (OCUL) shares increased by 28% in premarket trading as the company approaches key data readouts for its investigative drug, AXPAXLI. The SOL-1 trial for wet AMD has completed randomization and all participants have finished their Week 52 visits, with data presentation expected between February 25-28, 2026. The company plans to submit a New Drug Application for wet AMD based on these 52-week results, potentially shortening the FDA review timeline.
Landmark eye trial: two-thirds on AXPAXLI kept vision at 1 year
Ocular Therapeutix reported positive topline results for its AXPAXLI (OTX-TKI) in the SOL-1 Phase 3 superiority trial for wet AMD. The trial successfully met its FDA-aligned primary endpoint at Week 36, demonstrating that 74.1% of subjects maintained vision, and showed durable Week 52 outcomes with 65.9% maintaining vision, surpassing aflibercept. Despite these strong clinical results, the market reacted negatively, with Ocular Therapeutix (NASDAQ: OCUL) stock declining by 21.28% on the news day.
Ocular claims a win with Phase 3 eye drug data even as shares sink
Ocular Therapeutix announced positive Phase 3 trial results for its experimental eye disease drug, Axpaxli, showing it outperformed a low dose of Eylea in treating wet age-related macular degeneration. Despite the company's claim of a successful trial, Ocular's shares dropped by 23% as analysts noted the benefits were modest and the high success rate in the Eylea control arm disappointed investors. Ocular plans to seek FDA approval, entering a competitive market currently dominated by Eylea and Vabysmo.
Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes
Ocular Therapeutix's (NASDAQ:OCUL) shares dropped after topline Phase 3 results for its wet age-related macular degeneration (AMD) treatment, Axpaxli, underwhelmed investors despite demonstrating statistical significance. While Axpaxli showed a durability advantage over Eylea, the improvement was smaller than anticipated, leading to concerns about its commercial success in a competitive market. The company plans to submit a New Drug Application based on the SOL-1 data, aiming for Axpaxli to be the first tyrosine kinase inhibitor on the market for wet AMD.
Ocular Therapeutix Financial Results Disappoint Investors
Ocular Therapeutix Inc. (OCUL) stocks are down significantly by -23.54% following disappointing Q4 financial results, including a net loss of $0.29 per diluted share and a revenue decrease from $17.1M to $13.3M. The company faces challenges in profitability and sustainable revenue growth despite high liquidity, prompting investor concern and a call for strategic recalibration and operational efficiency from management. Traders are focusing on immediate strategic actions due to the current market volatility and financial strain.
Ocular Therapeutix (OCUL) Drops 22% Despite Positive Trial Resul
Ocular Therapeutix (OCUL) shares dropped 22% premarket following the release of Phase 3 SOL-1 trial data for its investigational wet AMD treatment, Axpaxli. Despite the stock decline, the trial showed positive results, with Axpaxli outperforming aflibercept in maintaining vision. The company plans to seek FDA approval for Axpaxli, aiming to introduce a novel tyrosine kinase inhibitor for wet AMD.
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial
Ocular Therapeutix's experimental eye drug has shown superiority to Regeneron's Eylea in a late-stage clinical trial. This news suggests a potential new competitive treatment option in the ophthalmology market.
Ocular Therapeutix stock tumbles after wet AMD trial results
Ocular Therapeutix's stock dropped 35% despite reporting positive Phase 3 trial results for its wet AMD treatment, AXPAXLI, which met its primary endpoint for vision maintenance. The company plans to submit a New Drug Application to the FDA, but investors remain concerned, reflecting potential data nuances or regulatory hurdles. Further data will be presented soon, and another Phase 3 trial is ongoing.
Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD
Ocular Therapeutix announced positive topline results from its SOL-1 Phase 3 superiority trial for AXPAXLI, an investigational product for wet age-related macular degeneration (wet AMD). The trial demonstrated AXPAXLI's superiority to aflibercept (2mg) in maintaining vision at Weeks 36 and 52, with high statistical significance, and showed favorable rescue-free rates and fluid control. The company plans to submit a New Drug Application (NDA) based on these results, which highlight AXPAXLI's potential to significantly reduce treatment burden and improve long-term visual outcomes for wet AMD patients.
Ocular Therapeutix's AXPAXLI Meets Superiority Endpoint In Wet AMD Trial, But Stock Down
Ocular Therapeutix announced positive topline results from its pivotal Phase 3 SOL-1 trial for AXPAXLI in wet age-related macular degeneration, demonstrating superiority over an approved therapy. Despite this significant scientific achievement, the company's stock fell over 27%. Ocular Therapeutix plans to submit a New Drug Application based on these results, which highlight AXPAXLI's potential for reduced treatment burden and high durability.
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
Sanofi has reportedly made a significantly revised bid for Ocular Therapeutix, ahead of the biotech company's crucial Phase 3 SOL-1 trial results. The acquisition could reshape the retinal disease market, with Ocular Therapeutix's AXPAXLI therapy holding the potential to offer superior, less frequent treatment for wet age-related macular degeneration. This aggressive move by Sanofi aims to preempt a valuation surge and re-establish its presence in the ophthalmology sector it previously exited.
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
Ocular Therapeutix (NASDAQ: OCUL) is on the verge of releasing crucial Phase 3 data for its wet Age-Related Macular Degeneration (AMD) treatment, AXPAXLI. This bioresorbable hydrogel implant aims to provide sustained release of axitinib for up to nine months, potentially ending "injection fatigue" for wet AMD patients. Analysts predict a significant binary event for the stock, with success potentially tripling its valuation and failure leading to a sharp decline.
Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026
Ocular Therapeutix, Inc. is set to announce topline results from its SOL-1 Phase 3 superiority clinical trial for AXPAXLI™ (OTX-TKI) in wet age-related macular degeneration (wet AMD) on Tuesday, February 17, 2026, via a webcast. Detailed data will subsequently be presented at the 49th Macula Society Annual Meeting from February 25-28, 2026. AXPAXLI™ is an investigational axitinib intravitreal hydrogel, and the company is focused on redefining retina treatment with its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology.
Assessing Ocular Therapeutix (OCUL) Valuation After Wider Losses And Potential Share Dilution
Ocular Therapeutix (OCUL) recently reported wider losses for Q4 and full year 2025, alongside a shelf registration for potential share dilution. Despite recent stock price pressure, some valuation models suggest the company is undervalued, driven by the potential of its retinal pipeline asset, AXPAXLI. The article raises questions about the company's path to profitability and the impact of future share issuance on investor stakes.
Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced that it will host a webcast on Tuesday, February 17, 2026, at 8:00 AM ET to review the topline results of its SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ for wet age-related macular degeneration (wet AMD). Detailed data from the trial will be presented later in February at the 49th Macula Society Annual Meeting. AXPAXLI™ is an investigational product candidate that leverages Ocular's ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology.
Ocular Therapeutix to Host Webcast Presenting SOL-1 Data for AXPAXLI™ on February 17, 2026
Ocular Therapeutix Inc. announced a webcast for February 17, 2026, to discuss topline results from the SOL-1 Phase 3 clinical trial of AXPAXLI™ for wet age-related macular degeneration. Detailed data will be presented later at the 49th Macula Society Annual Meeting. The company's pipeline includes AXPAXLI and DEXTENZA, with the webcast and data presentations expected to draw significant investor interest.
Ocular Therapeutix™ to Announce Topline Data for SOL-1
Ocular Therapeutix, Inc. will announce topline results for its SOL-1 Phase 3 superiorit y clinical trial of AXPAXLI™ for wet age-related macular degeneration on Tuesday, February 17, 2026, via a webcast. Detailed data from the trial will subsequently be presented at the 49th Macula Society Annual Meeting. The company, an integrated biopharmaceutical firm, is focused on redefining the retina experience with its ELUTYX™ bioresorbable hydrogel-based formulation technology.
Why It's Time To Keep A Close Eye On OCUL
Ocular Therapeutix Inc. (OCUL) is developing Axpaxli, an investigational treatment for wet age-related macular degeneration (AMD), with two Phase 3 trials, SOL-1 and SOL-R, currently underway. SOL-1's topline data is expected in late February 2026, and SOL-R's in Q1 2027. The company's sole marketed product, DEXTENZA, saw a revenue decline in 2025, while OCUL ended the year with $737.1 million in cash and cash equivalents.
How Investors Are Reacting To Ocular Therapeutix (OCUL) Revenue Miss And Widening 2025 Net Loss
Ocular Therapeutix (OCUL) reported a revenue miss and wider net losses for Q4 and full-year 2025, with quarterly revenue at US$13.25 million and annual revenue at US$51.95 million. Despite the financial shortfall, the company is advancing its ophthalmology pipeline, focusing on clinical outcomes for its AXPAXLI product, particularly SOL-1 data for wet AMD. The investment narrative largely depends on future trial readouts and eventual commercialization, rather than immediate profitability, as highlighted by the market's heavy weighing of these risks and the continued focus on talent retention through an equity plan.
How Investors Are Reacting To Ocular Therapeutix (OCUL) Revenue Miss And Widening 2025 Net Loss
Ocular Therapeutix (OCUL) reported a revenue miss and wider net losses for 2025, with quarterly revenue at US$13.25 million and annual revenue at US$51.95 million. Despite this, the company's loss per share was in line with the prior year, and it continues to advance its clinical programs. The investment narrative for OCUL heavily relies on the success of its ophthalmology pipeline and upcoming trial readouts rather than current financial performance.
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL)
Investment analysts have conflicting views on two healthcare companies: Illumina (ILMN) and Ocular Therapeutix (OCUL). While Illumina received Sell ratings from Bank of America Securities and Barclays, Ocular Therapeutix garnered Buy ratings from H.C. Wainwright and Piper Sandler, with significantly higher price targets. These ratings highlight divergent expert opinions on the future performance of these stocks within the healthcare sector.
Ocular Therapeutix (OCUL) Widening TTM Losses Reinforce Bearish Narratives Despite Revenue Growth Hopes
Ocular Therapeutix (OCUL) reported widening trailing 12-month (TTM) losses of US$265.94 million despite achieving US$51.95 million in revenue for FY 2025. This reinforces bearish views, as losses have increased over the past five years and the company is forecast to remain unprofitable for the next three. The company's high P/S ratio of 38.4x and recent insider selling and shareholder dilution also add to investor concerns, despite a DCF fair value estimate significantly above its current share price.
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility
Ocular Therapeutix (OCUL) has experienced recent stock price volatility, with short-term declines despite stronger long-term returns. Trading at US$8.91 against an intrinsic value estimate of US$24.58, the company appears undervalued, especially with the potential approval of AXPAXLI. However, analysts note a high Price-to-Sales ratio of 34x, suggesting the market is already pricing in future growth, creating a discrepancy between valuation models and market sentiment.
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement awards for five new non-executive employees under Nasdaq Listing Rule 5635(c)(4). The awards, effective February 2, 2026, include stock options to purchase 13,850 shares and restricted stock units for 4,600 shares, with specific vesting schedules. These grants are part of the company's 2019 Inducement Stock Incentive Plan to attract talent.
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement awards for five new non-executive employees under Nasdaq Listing Rule 5635(c)(4). These awards, consisting of stock options and restricted stock units, are intended to induce their acceptance of employment. The grants primarily vest over three to four years, subject to continued service.
Five new Ocular Therapeutix hires receive 18,450-share equity awards
Ocular Therapeutix (NASDAQ: OCUL) has granted inducement equity awards to five new non-executive employees, effective February 2, 2026. These awards include non-statutory stock options for 13,850 shares with an exercise price of $9.15, and restricted stock units for 4,600 shares, both vesting over several years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the new hires.
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility
Ocular Therapeutix (OCUL) has experienced recent stock volatility, but despite short-term dips, its longer-term performance remains strong. Trading at US$8.91 with an intrinsic value estimated around US$24.58, the stock appears significantly undervalued, largely due to the anticipated success of its drug AXPAXLI. However, the high price-to-sales ratio and reliance on future clinical and regulatory success for AXPAXLI introduce risks.
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement awards for five new non-executive employees under Nasdaq Listing Rule 5635(c)(4). These awards, granted on February 2, 2026, include stock options to purchase 13,850 shares and restricted stock units for 4,600 shares, both vesting over several years. The biopharmaceutical company specializes in retina treatments and has product candidates like AXPAXLI for wet AMD and diabetic retinal disease, and the FDA-approved DEXTENZA.
Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks
Ocular Therapeutix Inc. (OCUL) is facing significant regulatory risks due to disruptions at the FDA and other government agencies, which could delay product development and market entry. These delays stem from funding cuts, workforce reductions, and potential future public health emergencies, threatening the company's approval processes and ability to access capital. Despite these challenges, Wall Street analysts currently assign a Strong Buy consensus rating to OCUL stock.
Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financials, Provides Business Highlights
Ocular Therapeutix reported a decrease in total net revenue for Q4 and full year 2025, alongside an increased net loss and higher R&D expenses. The company provided business updates, including accelerated timing for clinical trial results of Axpaxli for wet AMD and the appointment of a global chief commercial officer to prepare for Axpaxli's global launch. Ocular Therapeutix also stated that its current cash balance is sufficient to support operations into 2028 following a recent equity offering.
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates
Ocular Therapeutix (NASDAQ:OCUL) reported Q4 CY2025 revenues of $13.25 million, missing analyst estimates by 11% and representing a 22.4% year-on-year decline. Despite the revenue miss, the company's non-GAAP loss of $0.29 per share was 13.9% better than consensus estimates. Analysts expect revenue to grow by 4.8% over the next 12 months, but project a decline in full-year EPS.
Ocular Therapeutix Inc earnings beat by $0.03, revenue fell short of estimates
Ocular Therapeutix Inc (NASDAQ: OCUL) reported fourth-quarter EPS of $-0.29, beating analyst estimates by $0.03, but revenue of $13.25M fell short of the consensus estimate of $16.13M. The company's stock closed at $8.55, showing a -21.20% decrease over the last three months and an 11.91% increase over the last 12 months. InvestingPro rates Ocular Therapeutix Inc's financial health as "weak performance."
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) reported a Q4 loss of $0.29 per share, which was better than the Zacks Consensus Estimate of a $0.33 loss, but revenue of $13.25 million missed estimates by 12.22%. The company's shares have underperformed the S&P 500 this year, and its near-term outlook, based on the Zacks Rank, suggests it will perform in line with the market. Another company in the same industry, Neurocrine Biosciences (NBIX), is expected to report its earnings soon.
Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Ocular Therapeutix (OCUL) announced its financial results for Q4 and full year 2025, reporting increased net losses and decreased revenue compared to 2024, attributed partly to a challenging reimbursement environment for DEXTENZA®. Simultaneously, the company provided updates on its clinical trials, including its pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline data expected in late February 2026. The company also secured $475 million in funding in September 2025, bolstering its cash balance to $737.1 million by year-end.
Ocular Therapeutix: Fourth Quarter Earnings Overview
Ocular Therapeutix Inc. reported a net loss of $64.7 million for the fourth quarter, or 29 cents per share, which was better than the 33 cents per share loss anticipated by analysts. The company's quarterly revenue was $13.3 million, falling short of the $15.1 million forecast. For the full year, Ocular Therapeutix recorded a total loss of $265.9 million, or $1.42 per share, with annual revenue of $52 million.
Eye drug trial data nears as Ocular Therapeutix amasses $737M cash
Ocular Therapeutix (NASDAQ: OCUL) reported Q4 and full-year 2025 financial results, with a widening net loss of $265.9M due to increased R&D spending on late-stage clinical trials for AXPAXLI. Despite a decrease in DEXTENZA revenue, the company maintains a strong cash position of $737.1M, projecting a runway into 2028. Key upcoming milestones include the release of SOL-1 Week 52 topline data in late February 2026, with plans to submit a New Drug Application (NDA) for AXPAXLI pending positive results.
